American Journal of Ophthalmology
Volume 137, Issue 1 , Pages 1-17 , January 2004

Ocular toxoplasmosis: a global reassessment: part II: disease manifestations and management

Presented at the annual meeting of the American Academy of Ophthalmology, Nov 16, 2003.

  • Gary N. Holland, MD

      Affiliations

    • Ocular Inflammatory Disease Center, Jules Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, California, USA.
    • Corresponding Author InformationInquiries to Gary N. Holland, MD, Jules Stein Eye Institute, 100 Stein Plaza, UCLA, Los Angeles, CA, USA 90095-7003; fax: (310) 794-7906

,Accepted 13 October 2003.

References 

  1. Holland GN. LX Edward Jackson Memorial Lecture. Ocular toxoplasmosis (A global reassessment. Part I: Epidemiology and course of disease). Am J Ophthalmol. 2003;136:973–988
  2. Hogan MJ. Ocular toxoplasmosis (XIV Edward Jackson Memorial Lecture). Am J Ophthalmol. 1958;46:467–494
  3. Wilder HC. Toxoplasma chorioretinitis in adults. Arch Ophthalmol. 1952;48:127–136
  4. Holland GN, O'Connor GR, Belfort R, Remington JS. Toxoplasmosis. In:  Pepose JS,  Holland GN,  Wilhelmus KR editor. Ocular infection & immunity. St. Louis, Missouri: Mosby-Year Book, Inc; 1996;p. 1183–1223
  5. Hogan MJ, Kimura SJ, O'Connor GR. Ocular toxoplasmosis. Arch Ophthalmol. 1964;72:592–600
  6. Friedmann CT, Knox DL. Variations in recurrent active toxoplasmic retinochoroiditis. Arch Ophthalmol. 1969;81:481–493
  7. O'Connor GR. Manifestations and management of ocular toxoplasmosis. Bull NY Acad Med. 1974;50:192–210
  8. Smith JR, Cunningham ET. Atypical presentations of ocular toxoplasmosis. Curr Opin Ophthalmol. 2002;13:387–392
  9. Fardeau C, Romand S, Rao NA, et al.  Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am J Ophthalmol. 2002;134:196–203
  10. Moshfeghi DM, Lowder CY, Dodds EM, et al. Diagnostic approaches to severe, atypical toxoplasmosis mimicking acute retinal necrosis. Ophthalmology; forthcoming
  11. Holland GN, Engstrom R, Glasgow BJ, et al.  Ocular toxoplasmosis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1988;106:653–667
  12. Holland GN. Ocular toxoplasmosis in the immunocompromised host. Int Ophthalmol. 1989;13:399–402
  13. Elkins BS, Holland GN, Opremcak EM, et al.  Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. 1994;101:499–507
  14. Cochereau-Massin I, LeHoang P, Lautier-Frau M, et al.  Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophthalmol. 1992;114:130–135
  15. Gagliuso DJ, Teich SA, Friedman AH, Orellana J. Ocular toxoplasmosis in AIDS patients. Trans Am Ophthalmol Soc. 1990;88:63–86
  16. Matthews JD, Weiter JJ. Outer retinal toxoplasmosis. Ophthalmology. 1988;95:941–946
  17. Doft BH, Gass DM. Punctate outer retinal toxoplasmosis. Arch Ophthalmol. 1985;103:1332–1336
  18. Silveira C, Belfort R, Muccioli C, et al.  A follow-up study of Toxoplasma gondii infection in southern Brazil. Am J Ophthalmol. 2001;131:351–354
  19. Fish RH, Hoskins JC, Kline LB. Toxoplasmosis neuroretinitis. Ophthalmology. 1993;100:1177–1182
  20. Roach ES, Zimmerman CF, Troost BT, Weaver RG. Optic neuritis due to acquired toxoplasmosis. Pediatr Neurol. 1985;1:114–116
  21. Holland GN, Muccioli C, Silveira C, et al.  Intraocular inflammatory reactions without focal necrotizing retinochoroiditis in patients with acquired systemic toxoplasmosis. Am J Ophthalmol. 1999;128:413–420
  22. Banta JT, Davis JL, Lam BL. Presumed toxoplasmosic anterior optic neuropathy. Ocul Immunol Inflamm. 2002;10:201–211
  23. Berger BB, Egwuagu CE, Freeman WR, Wiley CA. Miliary toxoplasmic retinitis in acquired immunodeficiency syndrome. Arch Ophthalmol. 1993;111:373–376
  24. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis (clinical features and prognosis of 154 patients). Ophthalmology. 2002;109:869–878
  25. Rothova A, Meenken C, Buitenhuis HJ, et al.  Therapy for ocular toxoplasmosis. Am J Ophthalmol. 1993;115:517–523
  26. Hoerni B, Vallat M, Durand M, Pesme D. Ocular toxoplasmosis and Hodgkin's disease (report of two cases). Arch Ophthalmol. 1978;96:62–63
  27. Yeo JH, Jakobiec FA, Iwamoto T, et al.  Opportunistic toxoplasmic retinochoroiditis following chemotherapy for systemic lymphoma (a light and electron microscopic study). Ophthalmology. 1983;90:885–898
  28. Nicholson DH, Wolchok EB. Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy. Arch Ophthalmol. 1976;94:248–254
  29. Johnson MW, Greven GM, Jaffe GJ, et al.  Atypical, severe toxoplasmic retinochoroiditis in elderly patients. Ophthalmology. 1997;104:48–57
  30. Labalette P, Delhaes L, Margaron F, et al.  Ocular toxoplasmosis after the fifth decade. Am J Ophthalmol. 2002;133:506–515
  31. Mets MB, Holfels E, Boyer KM, et al.  Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol. 1996;122:309–324
  32. Yang P, Das PK, Kijlstra A. Localization and characterization of immunocompetent cells in the human retina. Ocul Immunol Inflamm. 2000;8:149–157
  33. Schuman JS, Weinberg RS, Ferry AP, Guerry RK. Toxoplasmic scleritis. Ophthalmology. 1988;95:1399–1403
  34. Moorthy RS, Smith RE, Rao NA. Progressive ocular toxoplasmosis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 1993;115:742–747
  35. Rehder JR, Burnier MBJ, Pavesio CE, et al.  Acute unilateral toxoplasmic iridocyclitis in an AIDS patient. Am J Ophthalmol. 1988;106:740–741
  36. Bosch-Driessen LH, Karimi S, Stilma JS, Rothova A. Retinal detachment in ocular toxoplasmosis. Ophthalmology. 2000;107:36–40
  37. Gentile RC, Berinstein DM, Oppenheim R, Walsh JB. Retinal vascular occlusions complicating acute toxoplasmic retinochoroiditis. Can J Ophthalmol. 1997;32:354–358
  38. Schlaegel TFJ, Weber JC. The macula in ocular toxoplasmosis. Arch Ophthalmol. 1984;102:697–698
  39. Gilbert RE, Dunn DT, Lightman S, et al.  Incidence of symptomatic Toxoplasma eye disease (aetiology and public health implications). Epidemiol Infect. 1999;123:283–289
  40. Jones JL, Kruszon-Moran D, Wilson M, et al.  Toxoplasma gondii infection in the United States (seroprevalence and risk factors). Am J Epidemiol. 2001;154:357–365
  41. Silveira C, Belfort RJ, Burnier MJ, Nussenblatt R. Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am J Ophthalmol. 1988;106:362–364
  42. Glasner PD, Silveira C, Kruszon-Moran D, et al.  An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136–144
  43. Ronday MJ, Luyendijk L, Baarsma GS, et al.  Presumed acquired ocular toxoplasmosis. Arch Ophthalmol. 1995;113:1524–1529
  44. Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis. 1996;23:277–282
  45. Burnett AJ, Shortt SG, Isaac-Rentom J, et al.  Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology. 1998;105:1032–1037
  46. Pawelec G, Solana R, Remarque E, Mariani E. Impact of aging on innate immunity. J Leukoc Biol. 1998;64:703–712
  47. Grubeck-Loebenstein B, Wick G. The aging of the immune system. Adv Immunol. 2002;80:243–284
  48. Suzuki Y, Joh K, Orellana MA, et al.  A gene(s) within the H-2D region determines the development of toxoplasmic encephalitis in mice. Immunology. 1991;74:732–739
  49. Suzuki Y, Wong SY, Grumet FC, et al.  Evidence for genetic regulation of susceptibility to toxoplasmic encephalitis in AIDS patients. J Infect Dis. 1996;173:265–268
  50. Mack DG, Johnson JJ, Roberts F, et al.  HLA-class II genes modify outcome of Toxoplasma gondii infection. Int J Parasitol. 1999;29:1351–1358
  51. Nussenblatt RB, Mittal KK, Fuhrman S, et al.  Lymphocyte proliferative responses of patients with ocular toxoplasmosis to parasite and retinal antigens. Am J Ophthalmol. 1989;107:632–641
  52. Meenken C, Rothova A, de Waal LP, et al.  HLA typing in congenital toxoplasmosis. Br J Ophthalmol. 1995;79:494–497
  53. Holland GN, Cornell PJ, Park MS, et al.  An association between acute retinal necrosis syndrome and HLA-DQw7 and phenotype Bw62, DR4. Am J Ophthalmol. 1989;108:370–374
  54. Yamamoto JH, Vallochi AL, Silveira C, et al.  Discrimination between patients with acquired toxoplasmosis and congenital toxoplasmosis on the basis of the immune response to parasite antigens. J Infect Dis. 2000;181:2018–2022
  55. O'Connor GR. Factors related to the initiation and recurrence of uveitis (XL Edward Jackson Memorial Lecture). Am J Ophthalmol. 1983;96:577–599
  56. Howe DK, Sibley LD. Toxoplasma gondii comprises three clonal lineages (Correlation of parasite genotype with human disease). J Infect Dis. 1995;172:1561–1566
  57. Grigg ME, Bonnefoy S, Hehl AB, et al.  Success and virulence in Toxoplasma as the result of sexual recombination between two distinct ancestries. Science. 2001;294:161–165
  58. Su C, Evans D, Cole RH, et al.  Recent expansion of Toxoplasma through enhanced oral transmission. Science. 2003;299:414–416
  59. Sibley LD, Boothroyd JC. Virulent strains of Toxoplasma gondii comprise a single clonal lineage. Nature. 1992;359:82–85
  60. Su C, Howe DK, Dubey JP, et al.  Identification of quantitative trait loci controlling acute virulence in Toxoplasma gondii.. Proc Natl Acad Sci USA. 2002;99:10753–10758
  61. Barragan A, Sibley LD. Transepithelial migration of Toxoplasma gondii is linked to parasite motility and virulence. J Exp Med. 2002;195:1625–1633
  62. Boothroyd JC, Grigg ME. Population biology of Toxoplasma gondii and its relevance to human infection (do different strains cause different disease?). Curr Opin Microbiol. 2002;5:438–442
  63. Reynolds MG, Oh J, Roos DS. In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother. 2001;45:1271–1277
  64. Howe DK, Honoré S, Derouin F, Sibley LD. Determination of genotypes of Toxoplasma gondii strains isolated from patients with toxoplasmosis. J Clin Microbiol. 1997;35:1411–1414
  65. Honoré S, Couvelard A, Garin YJ, et al.  [Genotyping of Toxoplasma gondii strains from immunocompromised patients]. Pathol Biol (Paris). 2000;48:541–557
  66. Fuentes I, Rubio JM, Ramirez C, Alvar J. Genotypic characterization of Toxoplasma gondii strains associated with human toxoplasmosis in Spain (direct analysis from clinical samples). J Clin Microbiol. 2001;39:1566–1570
  67. Dubey JP, Graham DH, Blackston CR, et al.  Biological and genetic characterisation of Toxoplasma gondii isolates from chickens (Gallus domesticus) from Sao Paulo, Brazil (unexpected findings). Int J Parasitol. 2002;32:99–105
  68. Silveira CAM. A Maior Epidemia do Mundo. Toxoplasmose: Dúvidas e Controvérsias. Erechim, RS, Brazil: EdiFAPES, 2002:80
  69. Lehmann T, Blackston CR, Parmley SF, et al.  Strain typing of Toxoplasma gondii: comparison of antigen-coding and housekeeping genes. J Parasitol. 2000;86:960–971
  70. Grigg ME, Ganatra J, Boothroyd JC, Margolis TP. Unusual abundance of atypical strains associated with human ocular toxoplasmosis. J Infect Dis. 2001;184:633–639
  71. Kong JT, Grigg ME, Uyetake L, et al.  Serotyping of Toxoplasma gondii infections in humans using synthetic peptides. J Infect Dis. 2003;187:1484–1495
  72. Dubey JP, Sharma SP, Juranek DD, et al.  Characterization of Toxoplasma gondii isolates from an outbreak of toxoplasmosis in Atlanta, Georgia. Am J Vet Res. 1981;42:1007–1010
  73. Gilbert RE, Stanford MR, Jackson H, et al.  Incidence of acute symptomatic Toxoplasma retinochoroiditis in south London according to country of birth. BMJ. 1995;310:1037–1040
  74. Holland GN, Lewis KG. An update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:102–114 Erratum in Am J Ophthalmol 2002;134:944
  75. Engstrom RE, Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 1991;111:601–610
  76. Isaac-Renton J, Bowie WR, King A, et al.  Detection of Toxoplasma gondii oocysts in drinking water. Appl Environ Microbiol. 1998;64:2278–2280
  77. Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis (an evidence-based systematic review). Ophthalmology. 2003;110:926–931
  78. Gilbert RE, See SE, Jones LV, Stanford MS. Antibiotics versus control for toxoplasma retinochoroiditis (Cochrane review). The Cochrane Library, issue 1. Oxford: Update Software 2002
  79. Huskinson-Mark J, Araujo FG, Remington JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis. 1991;164:170–171
  80. Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology. 1999;106:148–153
  81. Lopez JS, De Smet MD, Masur H, et al.  Orally administered 566C80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol. 1992;113:331–333
  82. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al.  A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:34–40
  83. Sabates R, Pruett RC, Brockhurst RJ. Fulminant ocular toxoplasmosis. Am J Ophthalmol. 1981;92:497–503
  84. O'Connor GR, Frenkel JK. Editorial (Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy). Arch Ophthalmol. 1976;94:213
  85. Silveira C, Belfort R, Muccioli C, et al.  The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. Am J Ophthalmol. 2002;134:41–46
  86. Rieger H. Zur Klinik der im Erwachsenenalter erworbenen Toxoplasmose. Klin Monatsbl Augenh. 1951;119:459–476
  87. Wising P. Akut adult toxoplasmos med lymfadenopathi och chorioretinit [Acute adult toxoplasmosis with lymphadenopathy and chorioretinitis]. Nord Med. 1952;47:563–565
  88. Jackson E. Our new journal [Editorial]. Am J Ophthalmol. 1918;1:68–70

☆ Supported, in part, by Research to Prevent Blindness, Inc., New York, NY, the Skirball Foundation, Los Angeles, CA, and the David May II Endowed Professorship. Additional support was provided by the Emily Plumb Estate and Trust Gift for resources utilized in the Jules Stein Eye Institute Clinical Research Center. Dr. Holland is a recipient of a Research to Prevent Blindness Physician-Scientist Award.Additional material for this article can be found on ajo.com. doi:10.1016/j.ajo.2003.10.032

PII: S0002-9394(03)01319-9

doi: 10.1016/j.ajo.2003.10.032

American Journal of Ophthalmology
Volume 137, Issue 1 , Pages 1-17 , January 2004

Article Tools

* Image Usage & Resolution